Cepi to co-fund vaxxinity's pivotal phase 3 ub-612 heterologous booster trial to combat sars-cov-2 variants

Oslo, norway and dallas, april 06, 2022 (globe newswire) -- the coalition for epidemic preparedness innovations (cepi) and vaxxinity, inc. (nasdaq: vaxx), a us company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal phase 3 clinical trial of vaxxinity's next generation ub-612 covid-19 vaccine candidate as a heterologous – or ‘mix-and-match' – booster dose. cepi will provide up to $9.25m in funding.
VAXX Ratings Summary
VAXX Quant Ranking